Prometheus Laboratories and Bayer Schering Pharma have entered into an oncology-focused mutational analysis services agreement to identify existing and novel cancer-relevant mutations from various clinical samples.
Under the terms of this agreement, Bayer will provide clinical samples, while Prometheus will perform mutational analyses that characterise the presence or absence of existing and novel cancer-relevant mutations in them.
Prometheus will be compensated based on the number and complexity of mutational analyses it completes for Bayer.
The collaboration combines Prometheus’ proprietary oncology diagnostic CEER platform with Bayer’s oncology pipeline with the objective of stratifying patients to appropriate drug candidates and accelerating the development and market introduction of novel oncology therapeutic and diagnostic products.
